FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

HOUSTON, March 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the issuance of a new U.S. patent entitled "Fibroblast Cell Therapy for Treatment of Osteoporosis."

The United States Patent and Trademark Office has issued U.S. Patent No. 12,544,407 B2, dated February 10, 2026, further strengthening FibroBiologics' intellectual property portfolio in regenerative medicine and bone-related disorders.

The patent covers methods of treating bone diseases or disorders, including osteoporosis, through the administration of fibroblast cells. The claims encompass systemic or local administration of fibroblasts, including modified fibroblasts, to modulate bone remodeling by inhibiting osteoclast activity and/or promoting osteoblast activity.

Specifically, the issued patent includes claims directed to:

• Methods of treating osteoporosis through administration of fibroblasts expressing recombinant CXCR4 or recombinant hTERT.
• Dedifferentiated fibroblasts generated through expression of OCT4, NANOG, and/or SOX2.
• Fibroblasts selected for specific marker profiles, including CD73, CD56, CD140, CD105, CD90, CD36, and CD146.
• Administration of fibroblasts systemically or locally.
• Combination therapy with anti-inflammatory agents, including NF-kappa B inhibitors
  
  

Osteoporosis is a chronic and progressive condition characterized by reduced bone mass and structural deterioration of bone tissue, leading to increased fracture risk. The newly issued patent supports FibroBiologics' approach to leveraging fibroblasts as therapeutic agents capable of modulating bone resorption and bone formation pathways, including inhibition of RANK ligand (RANKL)-mediated osteoclast activation.

"This patent is more than a milestone, it's a bold step forward in our mission to rethink what's possible in regenerative medicine," said Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics. "Osteoporosis impacts millions of lives across the globe, often quietly and profoundly. We see fibroblasts not just as cells, but as catalysts for change, with the potential to transform the way we treat bone degeneration by tackling both inflammation and the rebuilding process at its core. That's the kind of innovation that truly excites us."

With this issuance, FibroBiologics further reinforces its strategy of developing proprietary fibroblast cell therapies designed to address significant unmet medical needs.

For more information, please visit FibroBiologics' website, email FibroBiologics at [e-mail] or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the scope and strength of the Company's intellectual property portfolio, the potential indications for FibroBiologics' programs, and the potential clinical benefits of fibroblasts and fibroblast-derived materials in regenerative medicine and bone-related disorders, including osteoporosis. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics' R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.

General Inquiries:
[e-mail]

Investor Relations:
Nic Johnson
Russo Partners
[phone]
[e-mail]

Media Contact:
Liz Phillips
Russo Partners
[phone]
[e-mail]